| In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Animal Nutrition | 262.6 | 220.1 | 243.8 | 213.2 | 213.6 | 236.5 | | |
| Human Nutrition | 128.3 | 139.2 | 64.8 | 31.1 | 22.0 | 15.3 | | |
| Intersegment Eliminations | 0.8 | 2.5 | 2.1 | 1.5 | 1.6 | | | |
| Total revenues | 390.8 | 359.3 | 308.6 | 244.3 | 235.6 | 251.7 | 173.8 | 164.9 |
| Revenue growth [+] | 8.8% | 16.4% | 26.3% | 3.7% | -6.4% | 44.9% | 5.4% | -7.1% |
| Animal Nutrition | 19.3% | -9.7% | 14.3% | -0.2% | -9.7% | | | |
| Human Nutrition | -7.8% | 114.7% | 108.8% | 41.1% | 44.3% | | | |
| Intersegment Eliminations | -68.0% | 19.0% | 40.0% | -6.3% | | | | |
| Cost of goods sold | 276.9 | 260.4 | 231.0 | 161.5 | 193.6 | 197.1 | 124.6 | 156.7 |
| Gross profit | 113.9 | 98.9 | 77.6 | 82.8 | 42.1 | 54.7 | 49.2 | 8.2 |
| Gross margin | 29.1% | 27.5% | 25.1% | 33.9% | 17.8% | 21.7% | 28.3% | 5.0% |
| Selling, general and administrative | 41.1 | 40.9 | 31.5 | 25.3 | 21.7 | 23.1 | 15.6 | 12.6 |
| Research and development | 2.6 | 3.3 | 2.3 | 2.4 | 2.2 | 1.6 | 1.7 | 1.4 |
| Other operating expenses | 2.3 | 6.6 | 7.1 | 6.6 | 5.4 | -24.3 | -0.2 | -1.6 |
| EBITDA [+] | 93.6 | 72.6 | 58.8 | 69.5 | 30.8 | 70.8 | 46.9 | 9.2 |
| EBITDA growth | 28.8% | 23.6% | -15.4% | 126.0% | -56.6% | 51.1% | 406.7% | -75.1% |
| EBITDA margin | 23.9% | 20.2% | 19.0% | 28.5% | 13.1% | 28.1% | 27.0% | 5.6% |
| Depreciation | 23.6 | 22.6 | 20.9 | 20.5 | 18.0 | 16.4 | 14.8 | 13.5 |
| EBITA | 69.9 | 50.1 | 37.9 | 49.1 | 12.8 | 54.4 | 32.1 | -4.3 |
| EBITA margin | 17.9% | 13.9% | 12.3% | 20.1% | 5.4% | 21.6% | 18.4% | -2.6% |
| Amortization of intangibles | 2.0 | 2.0 | 1.1 | 0.6 | | | | |
| EBIT [+] | 67.9 | 48.1 | 36.8 | 48.5 | 12.8 | 54.4 | 32.1 | -4.3 |
| EBIT growth | 41.1% | 30.9% | -24.1% | 279.9% | -76.5% | 69.6% | -848.0% | -117.7% |
| EBIT margin | 17.4% | 13.4% | 11.9% | 19.8% | 5.4% | 21.6% | 18.4% | -2.6% |
| Non-recurring items [+] | 14.3 | 6.3 | 5.2 | 0.4 | 0.1 | | 1.0 | |
| Asset impairment | 12.1 | 4.5 | 4.7 | 0.3 | 0.1 | | | |
| Loss (gain) on sale of assets | 0.3 | 1.8 | 0.5 | 0.2 | -2.6 | 2.1 | 1.0 | 0.7 |
| Legal settlement | 1.8 | | | | | | | |
| Interest expense, net [+] | 0.4 | 1.5 | 1.3 | 1.6 | 1.3 | 2.1 | 2.5 | 4.3 |
| Interest expense | 0.4 | 1.5 | 1.3 | 1.6 | 1.3 | 2.1 | 2.5 | 4.5 |
| Interest income | | | | | 0.0 | 0.0 | 0.0 | 0.2 |
| Other income (expense), net [+] | -2.1 | -1.7 | 0.0 | -0.4 | -0.4 | -0.4 | -0.4 | -0.8 |
| Gain (loss) on sale of assets | | | | | -2.6 | | | 0.7 |
| Gain (loss) on foreign currency transactions | -1.8 | -1.2 | 0.3 | | | | | |
| Other | -0.3 | -0.5 | -0.3 | -0.4 | -0.4 | -0.4 | -0.4 | -0.5 |
| Pre-tax income | 51.1 | 38.6 | 30.2 | 46.0 | 11.0 | 51.9 | 28.2 | -9.5 |
| Income taxes | 18.2 | 14.6 | 11.7 | 15.5 | 6.9 | 17.7 | 10.0 | -3.3 |
| Tax rate | 35.6% | 37.9% | 38.9% | 33.6% | 62.9% | 34.2% | 35.3% | 34.5% |
| Net income | 32.9 | 24.0 | 18.5 | 30.5 | 4.1 | 34.2 | 18.3 | -6.2 |
| Net margin | 8.4% | 6.7% | 6.0% | 12.5% | 1.7% | 13.6% | 10.5% | -3.8% |
| |
| Basic EPS [+] | $1.50 | $1.13 | $0.90 | $1.53 | $0.21 | $1.78 | $0.97 | ($0.33) |
| Growth | 33.3% | 25.3% | -41.4% | 632.5% | -88.2% | 82.8% | -393.3% | -100.0% |
| Diluted EPS [+] | $1.48 | $1.10 | $0.87 | $1.48 | $0.20 | $1.71 | $0.97 | ($0.33) |
| Growth | 34.2% | 26.5% | -41.0% | 623.4% | -88.1% | 77.6% | -391.5% | -148.2% |
| |
| |
| Shares outstanding (basic) [+] | 21.9 | 21.3 | 20.6 | 19.9 | 19.4 | 19.2 | 18.8 | 18.7 |
| Growth | 2.9% | 3.6% | 3.3% | 2.5% | 0.9% | 2.3% | 0.4% | 2752105.9% |
| Shares outstanding (diluted) [+] | 22.2 | 21.7 | 21.2 | 20.6 | 19.9 | 19.9 | 18.9 | 18.7 |
| Growth | 2.2% | 2.7% | 2.6% | 3.8% | -0.2% | 5.4% | 1.0% | 2.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |